
Bree Collaborative | Treatment for OUD Revision

September 17th, 2024 | 3-4:30PM

Hybrid

MEMBERS PRESENT VIRTUAL

Charissa Fotinos, MD, WA HCA

Tawnya Christiansen, MD, CHPW

Libby Hein, CHPW

Tom Hutch, MD, We Care Daily

John Olson,

Amanda McPeak, PharmD, Kelley-Ross

Liz Wolkin, HCA

Jason Fodeman, MD, L&I

Maureen Oscadal, RN, CARN, Harborview

Tina Seery, RN, MHA, CPHQ, CPPS, CLSSBB,
WSHA

Dan Floyd, King County

Herbie Duber, DOH

Cris DuVall, Island Drug

Everett Maroon, Blue Mountain Heart to Heart

Ryan Caldeiro, MD, KP

STAFF AND MEMBERS OF THE PUBLIC

Beth Bojkov, MPH, RN, Bree Collaborative

Emily Nudelman, DNP, RN, Bree Collaborative

Emily Nudelman, DNP, RN, Bree Collaborative

Karin Inderbitzin, HCA

Jaquelyn Harmon,

Tim Candela, DOH

Hillary Norris, WSMA

Fan Xiong, DOH

WELCOME

Beth Bojkov, Bree Collaborative Staff welcomed the group to the August meeting and reviewed the agenda for the day.

Action: Unanimously approved August meeting minutes.

PRESENT & DISCUSS: TREATMENT FOR OUD REPORT GUIDELINES

Beth transitioned the group to reviewing the Treatment for OUD Report and Guidelines. The goal of the meeting is to review all stakeholder specific guidelines to get the report ready for public comment period. The following changes were made through discussion:

1. Clarified screening guidance for providers in primary care settings versus other settings
2. Encourage screening for adolescents despite vague USPSTF guidelines
3. Encourage providers to pay attention to local demographic trends
4. Added guidelines “ Prescribe MOUD for adequate duration. There is no limit on how long an individual may use any MOUD, and shorter prescription lengths (e.g., 1-2 weeks) may introduce unnecessary barriers to MOUD access.”
5. Rewrote benzodiazepine guidance -> “Treatment of opioid use disorder with medications should not be discouraged or delayed, but the combined use of these drugs increases the risk of serious side effects; however, the harm caused by untreated opioid addiction can outweigh these risks”
6. Remove all prior authorizations for MOUD, similar to Medicaid plans
7. Support community pharmacies **and healthcare facilities** seeking REMS certification

8. Correctional Facilities: consider offering and providing long-acting buprenorphine before release date

PUBLIC COMMENT AND GOOD OF THE ORDER

Beth invited final comments or public comments, then thanked all for attending. At the next workgroup, we will review and seek feedback on our checklist implementation tool and evaluation framework/matrix to support the implementation and evaluation of the report and guidelines into practice. The report will be up for public comment **until October 24th at 11:59PM**, and the workgroup's next meeting will be on **October 15th, 2024, 3-4:30PM**.